Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

head and neck squamous cell carcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) c-Met/HGFR (1) Checkpoint Kinase (Chk) (1) DYRK (1) EGFR (2) IFNAR (1) Ligands for E3 Ligase (1) Orphan Receptor (1) PKC (1) Reactive Oxygen Species (1)
By Research Areas:	Cancer (10) Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor Fat Mass and Obesity-associated Protein (FTO) VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99032

Monalizumab 2 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

HY-P99461

Barecetamab ISU-104	EGFR	Cancer
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .

HY-15673

KP372-1 2 Publications Verification	Akt Reactive Oxygen Species Apoptosis	Cancer
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) .

HY-149913

NR2F1 agonist 1	Orphan Receptor Others	Cancer
NR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model .

HY-109076

Tigilanol tiglate EBC-46	PKC	Cancer
Tigilanol tiglate (EBC-46) is a protein kinase C (PKC)/C1 domain activator. Tigilanol tiglate is a natural product with antitumor activity used for local administration against a variety of skin malignancies. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein response (UPRmt/ER) and subsequent induction of ATP depletion, organelles expansion, caspase activation, gasdermin E cleavage, and terminal necrosis. Tigilanol tiglate, as a small anti-tumor molecule with immunomodulatory effects, can be used in the study of head and neck squamous cell carcinoma and soft tissue sarcoma .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .

HY-144617

JH-XIV-68-3	DYRK	Cancer
JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

Cat. No.	Product Name	Target	Research Area

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

Cat. No.	Product Name

HY-K6111

*Human Head* and Neck Squamous Cell Carcinoma Organoid Kit**
MCE Human Head and Neck Squamous Cell Carcinoma Organoid Kit contains Head and Neck Squamous Cell Carcinoma Organoid Basal Medium A, Head and Neck Squamous Cell Carcinoma Organoid Supplement B (50×), Head and Neck Squamous Cell Carcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human head and neck squamous cell carcinoma organoid.

Human Head and Neck Squamous Cell Carcinoma Organoid Kit

MCE Human Head and Neck Squamous Cell Carcinoma Organoid Kit contains Head and Neck Squamous Cell Carcinoma Organoid Basal Medium A, Head and Neck Squamous Cell Carcinoma Organoid Supplement B (50×), Head and Neck Squamous Cell Carcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human head and neck squamous cell carcinoma organoid.

Cat. No.	Product Name	Target	Research Area

HY-P99208

Lirilumab 2 Publications Verification IPH2102	Inhibitory Antibodies	Cancer
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99032

Monalizumab 2 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

HY-P99461

Barecetamab ISU-104	EGFR	Cancer
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.